摘要
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是最常见的急性白血病之一,发病急、进展快,化疗和移植的规范化应用已极大改善患者预后,但仍存在未满足的治疗需求。近年以双特异性T细胞衔接器(Bispecific T cell Engager,BiTE)为代表的免疫治疗发展迅速,为ALL治疗提供了更多选择,同时也对临床诊疗管理提出了更高的要求。专家组基于国内外最新循证医学证据、相关指南和临床实践,对2022年版《双特异性T细胞衔接器治疗急性淋巴细胞白血病指导原则》进行更新,制定了该版中国专家共识。
Acute lymphoblastic leukemia(ALL)is one of the most common acute leukemias,with rapid onset and progression.The standardized application of chemotherapy and transplantation have improved the prognosis of patients,while the unmet therapeutic needs still exist.Recently novel immunotherapies including Bispecific T cell Engager develop rapidly,offering more options for ALL treatment and also demanding higher requirements for clinical diagnosis and treatment management.Based on the evidence of domestic and international medical evidence and clinical experience,the expert panel updated Chinese consensus for the Bispeific T cell Engager in the treatment of B-cell acute lymphoblastic leukemia(2022)and formulated this edition of the Chinese expert consensus.
作者
中国临床肿瘤学会白血病专家委员会
中国临床肿瘤学会淋巴瘤专家委员会
中华医学会血液学分会
中国医师协会血液科医师分会
马军
王建祥
吴德沛
黄晓军
Union for China Leukemia&Lymphoma Investigators of Chinese Society of Clinical Oncology;Chinese Society of Hematology,Chinese Medical Association;Chinese Hematology Association,Chinese Medical Doctor Association;Ma Jun;Wang Jianxiang;Wu Depei;Huang Xiaojun(不详;Department of Hematology&Oncology,Harbin Institute of Hematology&Oncology,Harbin 150010,China;Institute of Hematology&Blood Disease Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Tianjin 300020,China;the First Affiliated Hospital of Soochow University,Suzhou 215006,China;Peking University People'sHospital,Peking University Institute of Hematology,Beijing 100044,China)
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2024年第7期629-636,共8页
Chinese Journal of Hematology
